Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
Saizeng Medical Technology Co. Ltd, a subsidiary of Changchun High‑Tech Industry (Group) Co., Ltd. (SHE:...
Saizeng Medical Technology Co. Ltd, a subsidiary of Changchun High‑Tech Industry (Group) Co., Ltd. (SHE:...
Zhicheng Medical Technology (Jiaxing) Co., Ltd. announced that its self‑developed ReachTact Transcatheter Aortic Valve Replacement...
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) announced that ENHERTU (fam-trastuzumab deruxtecan-nxki) in...
The U.S. Food and Drug Administration (FDA) announced a major policy shift to accept Real-World...
Sanofi (NASDAQ: SNY) announced that the Phase 3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive...
Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced first patient dosing in the Phase 2 KC1036‑COM‑01...
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA selected the teclistamab MajesTEC‑3 supplemental...
uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next‑generation...
Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop...
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non‑exclusive agreements with Pfizer Inc. (NYSE: PFE) to...
Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...
UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency’s Committee for...
Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) announced a definitive agreement to acquire Arthrosi Therapeutics,...
Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s Committee for Medicinal Products...
Innovent Biologics, Inc. (HKG: 1801) announced that mazdutide received marketing approval from Macau’s drug regulatory...
Kyinno Biotechnology, a China‑based biotech company, announced the completion of its Series B financing round...
Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...
Akeso Biopharma (HKG: 9926) announced that the U.S. FDA approved cadonilimab in combination with chemotherapy...
The National Healthcare Security Administration (NHSA) released a notice to optimize healthcare fund settlement management,...
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and...